$69.65 -$1.65 (0.0%)

03:54 PM EDT on 07/18/19

Omnicell, Inc. (NASDAQ:OMCL)

CAPS Rating: 5 out of 5

The Company is a provider of medication control and patient safety solutions for acute care health facilities.

Current Price $69.65 Mkt Cap $2.9B
Open $71.00 P/E Ratio 0.00
Prev. Close $69.65 Div. (Yield) $1.63 (0.0%)
Daily Range $69.25 - $71.23 Volume 79,692
52-Wk Range $57.81 - $92.58 Avg. Daily Vol. 6

Caps

How do you think NASDAQ:OMCL will perform against the market?

Add Stock to CAPS Watchlist

All Players

181 Outperform
9 Underperform
 

All-Star Players

42 Outperform
1 Underperform
 

Wall Street

7 Outperform
1 Underperform
 

Top NASDAQ:OMCL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

pegburt (< 20)
Submitted May 06, 2008

yea, the owner of this company has like 9 kids. he's pretty cool. i think this a good company. seanmcb doesn't know s h i t. he's my 13 year old brother

CrankyTexan (99.73)
Submitted October 18, 2007

I am a registered nurse who has used Omnicell machines. I hate them. In my opinion, they are a pain in the butt and they slow down my job. When I am rushing to get an item during surgery, the last thing I want to do is swipe my I.D. card, swipe the… More

NASDAQ:OMCL VS S&P 500 (SPY)

Fools bullish on NASDAQ:OMCL are also bullish on:

Fools bearish on NASDAQ:OMCL are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about OMCL.

Recs

0
Member Avatar rknapton (83.23) Submitted: 8/22/2013 4:48:21 PM : Outperform Start Price: $22.55 NASDAQ:OMCL Score: +129.64

Long. Great growth story. Revs up 24% last quarter, earnings up 337%. Trading at 36x ttm earnings and 19x fye estimates so pricey but deservedly so for the growth.

Recs

0
Member Avatar jimbendt (27.93) Submitted: 4/10/2010 2:42:37 AM : Outperform Start Price: $13.96 NASDAQ:OMCL Score: +249.55

Can OMCL flourish in a super managed care environment?

Recs

0
Member Avatar Kinzo (99.73) Submitted: 4/3/2009 4:33:15 PM : Outperform Start Price: $7.90 NASDAQ:OMCL Score: +519.75

Finally a solution for a doctor's poor handwriting! Get it automated! In all seriousness however, my best friend's grandfather died after receiving the wrong medication while in the hospital. Having OMCL's medication-management products may have prevented such a terrible thing from happening.

Although they aren't the biggest player in the market (Pyxis is), they are still gobbling up market share since they are ahead of the technology curve. Also, by specializing in medication-management products only, this allows the entire company to focus on its product. Oh and requiring 12-18 month software upgrades is nice too (for additional recurring revenues).

Leaderboard

Find the members with the highest scoring picks in OMCL.

Score Leader

Peterhaze

Peterhaze (< 20) Score: +593.79

The Score Leader is the player with the highest score across all their picks in OMCL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Peterhaze < 20 1/22/2009 Outperform 3Y $7.27 +858.05% +264.26% +593.79 0 Comment
Kinzo 99.73 4/6/2009 Outperform 5Y $7.90 +781.65% +261.90% +519.75 1 Comment
bmoneyman 54.31 2/4/2009 Outperform 3Y $8.15 +754.60% +260.37% +494.23 0 Comment
go4amiller < 20 10/23/2008 Outperform 3Y $8.58 +711.77% +238.48% +473.29 1 Comment
GUESSER2 < 20 4/16/2009 Outperform 3M $8.63 +707.07% +253.05% +454.02 0 Comment
tjensen3618 52.77 4/24/2009 Outperform 3Y $8.75 +696.00% +247.91% +448.09 0 Comment
groot2000 93.27 10/30/2009 Outperform 3Y $9.84 +607.83% +183.16% +424.67 0 Comment
rumblinantliquid < 20 12/1/2009 Outperform 5Y $10.24 +580.18% +169.12% +411.06 0 Comment
cole1man 63.01 11/6/2009 Outperform 5Y $10.11 +588.92% +179.58% +409.34 0 Comment
issac25 97.91 4/24/2008 Outperform NS $11.04 +530.89% +122.61% +408.28 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackTopeka 22.41 6/13/2014 Outperform NS $27.16 +156.44% +53.95% +102.50 0 Comment
TrackFBRCapitalM 85.14 10/31/2013 Outperform NS $23.40 +197.65% +69.46% +128.19 0 Comment
TrackBRileyandCo < 20 2/21/2013 Outperform NS $17.94 +288.24% +97.74% +190.50 0 Comment
trackbenchmark 99.65 1/25/2013 Outperform NS $16.25 +328.62% +99.16% +229.45 0 Comment
TrackZacks < 20 8/2/2012 Outperform 3M $13.17 +10.33% +3.15% +7.17 8/15/2012 @ $14.53 1 Comment
TrackZacks < 20 5/29/2012 Outperform 3M $13.56 +3.91% -0.68% +4.59 6/29/2012 @ $14.09 1 Comment
TrackZacks < 20 5/3/2012 Outperform 3M $14.84 -4.38% -5.06% +0.68 5/23/2012 @ $14.19 1 Comment
TrackStifel 91.01 6/14/2011 Outperform NS $13.99 +397.86% +131.63% +266.22 0 Comment
TrackFBRCapitalM 85.14 9/23/2010 Underperform NS $11.98 +43.57% +15.46% -28.11 7/29/2011 @ $17.20 0 Comment
TrackAurigaUSA 61.85 6/10/2010 Outperform NS $12.25 +468.57% +176.75% +291.82 0 Comment
TrackZacks < 20 4/9/2010 Outperform 3M $13.94 +6.89% +17.16% -10.27 3/13/2012 @ $14.90 1 Comment
TrackCarisandCo 85.64 7/24/2009 Outperform NS $11.35 +513.66% +208.55% +305.11 0 Comment
TrackAurigaUSA 61.85 5/1/2009 Outperform NS $10.00 +5.20% +25.34% -20.14 10/20/2009 @ $10.52 0 Comment
TrackBBTCapMkts 32.21 1/21/2009 Underperform NS $7.05 +887.94% +273.93% -614.01 0 Comment
TrackAurigaUSA 61.85 1/21/2009 Underperform NS $6.41 +36.66% -2.76% -39.42 2/18/2009 @ $8.76 0 Comment
TrackAurigaUSA 61.85 12/17/2008 Outperform NS $12.30 -47.89% -10.26% -37.63 1/21/2009 @ $6.41 0 Comment
TrackBBTCapMkts 32.21 2/8/2008 Outperform NS $18.28 -61.71% -39.13% -22.58 1/21/2009 @ $7.00 0 Comment
TrackCarisandCo 85.64 2/4/2008 Outperform NS $20.25 -62.96% -39.86% -23.10 1/30/2009 @ $7.50 0 Comment
TrackBBTCapMkts 32.21 7/20/2007 Outperform NS $23.95 +21.29% +0.65% +20.64 10/10/2007 @ $29.05 0 Comment
TrackBroadpointAmTech < 20 10/30/2006 Outperform NS $18.55 -35.90% +0.16% -36.07 4/22/2008 @ $11.89 0 Comment
TrackMatrix < 20 9/13/2006 Underperform NS $18.00 -21.44% +4.84% +26.29 4/17/2012 @ $14.14 0 Comment

Advertisement